BACKGROUND: To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). METHODS: SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2-, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1-3) and five additional predefined risk factors. Recommendations were classified as hormonal therapy (HT) or chemotherapy plus HT (CT + HT). Investigators were blinded to the statistical analysis plan. A 5%/10% rate of recommendation change in LR/NLR groups, respectively, was assumed independently o...
Purpose: The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurren...
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...
To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whet...
Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene ...
BACKGROUND To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ...
Data de publicació electrònica: 18/02/2021Background: Predicting the risk of recurrence and response...
Background: The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence sco...
PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information...
AbstractPurposeThe 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive infor...
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...
International audienceBACKGROUND:The 21-gene Oncotype DX Recurrence Score assay is a validated assay...
Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is ...
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate onc...
Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Scor...
Aim MINDACT concluded that all breast cancer patients with a high clinical risk using a modified ver...
Purpose: The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurren...
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...
To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whet...
Abstract Background To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene ...
BACKGROUND To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ...
Data de publicació electrònica: 18/02/2021Background: Predicting the risk of recurrence and response...
Background: The Breast DX Italy prospective study evaluated the impact of the 21-gene recurrence sco...
PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information...
AbstractPurposeThe 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive infor...
Introduction: Oncotype DX recurrence score is used to categorize estrogen-receptor-positive, human e...
International audienceBACKGROUND:The 21-gene Oncotype DX Recurrence Score assay is a validated assay...
Predicting the risk of recurrence and response to chemotherapy in women with early breast cancer is ...
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate onc...
Background: The ROXANE Italian prospective study evaluated the impact of the 21-gene Recurrence Scor...
Aim MINDACT concluded that all breast cancer patients with a high clinical risk using a modified ver...
Purpose: The 21-gene breast cancer assay recurrence score (RS) is widely used for assessing recurren...
Background: The 21-gene recurrence score (RS) predicts risk of locoregional recurrence (LRR) in node...
To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whet...